Counter changes with changelessness: cope with SARS-CoV-2 immune evasion by targeting cryptic epitopes

References

[1] Yu F, Song H, Wu Y, et al. A potent germline-like human monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe 2017;22:471–83.

[2] Bangaru S, Lang S, Schotsaert M, et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 2019;177:1136–52.

[3] Watanabe A, McCarthy KR, Kuraoka M, et al. Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism. Cell 2019;177:1124–35.

[4] Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602:657–657.

[5] Li C, Zhan W, Yang Z, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell 2022;185(8):1389–401.

[6] Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9:382–5.

[7] Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630–3.

[8] Starr TN, Czudnochowski N, Liu Z, et al. SARS-CoV-2 RBD anti-bodies that maximize breadth and resistance to escape. Nature 2021;597:97–102.

[9] Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 2020;182:1295–310.

RIGHTS & PERMISSIONS

2022 The Author(s) 2022